Ngenla 24 mg – Pfizer – Australia

Description

Ngenla 24 mg – Pfizer – Australia

Ngenla 24 mg – Pfizer – Australia is a once-weekly long-acting growth hormone therapy containing somatrogon, developed by Pfizer for the treatment of pediatric growth hormone deficiency (GHD). Unlike traditional daily HGH injections, Ngenla’s advanced extended-release formula supports stable growth hormone levels with fewer injections, improving convenience and adherence for children from 3 years of age and older with insufficient natural growth hormone production. The 24 mg disposable prefilled pen delivers precise, adjustable weekly dosing via subcutaneous injection, supporting height velocity, metabolic function, and normal growth progression when prescribed by a healthcare professional. Requires prescription and medical supervision.